Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

[INTRODUCTION AND METHODS] Cancer therapy-related cardiac dysfunction (CTRCD) is a well established and potentially life-threatening complication of contemporary oncologic treatment. Although comprehensive cardio-oncology guidelines have been developed, their integration into routine hematology and oncology practice remains inconsistent. This consensus statement, developed by a multidisciplinary panel of cardio-oncology experts, aims to provide practical, case-based guidance to help oncology providers recognize, assess, and manage CTRCD across a spectrum of malignancies and cardiovascular presentations.

[CLINICAL SCENARIOS AND DISCUSSION] We present representative clinical scenarios that illustrate real-world challenges in cardio-oncology and apply evidence-based recommendations from current guidelines, including those from the European Society of Cardiology (ESC) and the International Cardio-Oncology Society (ICOS)-to support informed decision-making. Key areas of focus include baseline cardiovascular risk stratification prior to initiating potentially cardiotoxic therapies, with an emphasis on biomarker and imaging surveillance strategies tailored to individual risk profiles. Also, this document outlines the application of guideline-directed medical therapy (GDMT) for cancer patients with heart failure.

[CONCLUSION] By offering a structured, user-friendly framework, this document seeks to bridge the implementation gap between oncology and cardiology disciplines. Our goal is to equip oncology providers with accessible tools that facilitate early recognition, consistent surveillance, and timely referral, thereby preserving cancer treatment intensity while minimizing cardiovascular morbidity.